Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: Consistency across subgroups in the African-American Heart Failure Trial

Circulation

Volumn 115, Issue 13, 2007, Pages 1747-1753

  Taylor, Anne L ^a   Ziesche, Susan ^b   Yancy, Clyde W ^c   Carson, Peter ^d   Ferdinand, Keith ^e   Taylor, Malcolm ^f   Adams, Kirkwood ^g   Olukotun, Adeoye Y ^h   Ofili, Elizabeth ⁱ   Tam, S William ^j   Sabolinski, Michael L ^j   Worcel, Manuel ^j   Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e XAVIER UNIVERSITY OF LOUISIANA   (United States)

^f Association of Black Cardiologists   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Clinical and Regulatory Strategies   (United States)

ⁱ MOREHOUSE SCHOOL OF MEDICINE   (United States)

^j NitroMed Inc   (United States)

more..

Author keywords

African Americans; Cardiovascular diseases; Heart failure; Nitric oxide; Trials

Indexed keywords

HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PLACEBO; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; HYDRALAZINE; ISOSORBIDE DINITRATE; NITRIC OXIDE DONOR; VASODILATOR AGENT;

ABSENCE OF SIDE EFFECTS; AFRICAN AMERICAN; AGE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG DOSE TITRATION; DRUG EFFECT; HEART FAILURE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; SEX; ADULT; AGED; ARTHRALGIA; BLOOD; CAUSE OF DEATH; CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HEART TRANSPLANTATION; HYPOTENSION; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STATISTICS; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ARTHRALGIA; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; DIZZINESS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMANS; HYDRALAZINE; HYPOTENSION; ISOSORBIDE DINITRATE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE DONORS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34247182008     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.644013     Document Type: Article

References (36)

1. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn J; for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
2. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314:1547-1552.
3. Carson P, Ziesche S, Johnson G, Cohn J; for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail. 1999;5:178-187.
4. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M; A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:128-135.
5. Taylor AL. The African-American Heart Failure Trial (A-HeFT): rationale and methodology. J Card Fail. 2003;9:S216-S219.
6. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure, pt 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail J. 1987;3:198-209.
7. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughest GR, Bernstein R, Ryan P, Naish PF, Aber GM, Bing RF, Russell GI. Hydralazine-induced systematic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1980;1:1107-1109.
8. Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, Westergren G, Thimell M. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial of congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-2007.
9. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhas KL, Janosi A, Thorgeirsson G, Dunselman PHJM, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302.
10. Packer M, Coats AJS, Fowler M, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
11. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Hocslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194-2199.
12. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA; for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation. 1990;82:774-780.
13. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F III, DeMets DL, White BG; for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339:1810-1816.
14. Cowley AJ, Skene AM; for the Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J. 1994;72:226-230.
15. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pederson C, Ball S, Pogue J, Moye L, Braunwald E; for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
16. Jon P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843-1848.
17. Garg R, Yusuf S; for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
18. Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
19. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S; for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-765.
20. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN; for the Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970-975.
21. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Roulea JL, Rutherford J, Wertheimer JH, Hawkins CM; on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
22. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril (V-HeFT III). Circulation. 1997;96:856-863.
23. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49:40-42.
24. Ignarro L, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide. Circ Res. 2002;90:21-28.
25. Bauer J, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35-39.
26. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
27. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerine tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest. 1996;98:1465-1470.
28. Recchia FA, Osorio JC, Chandler MP, Xu X, Panchal AR, Lopaschuk GD, Hintze TH, Stanley WC. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol Endocrinol Metab. 2002;282:E197-E206.
29. Loke KE, Laycock SK, Mital S, Wollin MS, Bernstein R, Oz M, Addonizio L, Kaley G, Hintze TH. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation. 1999;100:1291-1297.
30. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res. 2004:94;1256-1262.
31. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res. 2004;94:1155-1157.
32. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aertz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286 -1291.
33. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerine induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35-39.
34. Cohn JN, Anand I, Taylor A, Tam SW, Sabolinski M, Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left-ventricular remodeling in a well-treated black population with heart failure: results from A-HEFT. J Card Fail. In press.
35. Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman DE, Hayes D, Farnham DJ, Randall OS, Dinh H, Arnold JMO, Kupersmith J, Hager D, Glasser SP, Biddle T, Hawkins CM, Braunwald E; for the SAVE Investigators. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Eur Heart J. 1994;15(suppl B):2-8.
36. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J. 2000;139:952-961.